"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar. Click to show full abstract

Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar.

Keywords: randomized study; iii randomized; phase iii; proposed adalimumab; psoriasis; adalimumab biosimilar

Journal Title: British Journal of Dermatology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended